Kura Oncology, Inc. (KURA)

Price$8.74

Value ScoreC

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-35.93%

Price vs S&P 500 (4W)-7.21%

VGM Score56.51

Market Capitalization$775.89M

All Metrics

P/CF (Annual)5.80x

Book Value / Share (Quarterly)$1.22

P/TBV (Annual)1.69x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.95

Price vs S&P 500 (YTD)-24.04%

Net Profit Margin (TTM)-411.19%

EPS (TTM)$-3.35

10-Day Avg Trading Volume2.19M

EPS Excl Extra (TTM)$-3.35

EPS (Annual)$-3.18

ROI (Annual)-151.58%

Gross Margin (Annual)99.92%

Cash / Share (Quarterly)$6.50

Revenue Growth QoQ (YoY)29.47%

ROA (Last FY)-37.74%

EBITD / Share (TTM)$-3.60

ROE (5Y Avg)-59.72%

Operating Margin (TTM)-443.54%

Cash Flow / Share (Annual)$-0.80

P/B Ratio7.19x

P/B Ratio (Quarterly)6.66x

Net Income / Employee (Annual)$-1,071,800

EV / Revenue (TTM)10.42x

Net Interest Coverage (TTM)-252.07x

ROA (TTM)-43.28%

EPS Incl Extra (Annual)$-3.18

Current Ratio (Annual)6.06x

Quick Ratio (Quarterly)5.81x

3-Month Avg Trading Volume1.60M

52-Week Price Return33.03%

EV / Free Cash Flow (Annual)5.19x

Revenue / Employee (TTM)$275,500

Tangible BV / Share (Quarterly)$5.79

P/S Ratio (Annual)11.50x

Asset Turnover (Annual)0.09x

52-Week High$12.49

EPS Excl Extra (Annual)$-3.18

CapEx CAGR (5Y)25.06%

Tangible BV CAGR (5Y)39.39%

26-Week Price Return-28.01%

Quick Ratio (Annual)5.78x

13-Week Price Return2.70%

Total Debt / Equity (Annual)0.06x

Current Ratio (Quarterly)6.15x

Enterprise Value$746.55M

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-26.48%

Revenue / Employee (Annual)$259,500

Pretax Margin (Annual)-412.51%

Cash / Share (Annual)$7.55

3-Month Return Std Dev62.58%

Net Income / Employee (TTM)$-1,133,000

ROE (Last FY)-160.03%

Net Interest Coverage (Annual)-122.19x

EPS Basic Excl Extra (Annual)$-3.18

Receivables Turnover (TTM)2.47x

EV / Free Cash Flow (TTM)8.35x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-3.35

ROI (TTM)-135.62%

P/S Ratio (TTM)10.83x

Revenue / Share (Annual)$0.77

Tangible BV / Share (Annual)$6.15

Price vs S&P 500 (52W)8.66%

Year-to-Date Return-15.88%

5-Day Price Return-3.27%

EPS Normalized (Annual)$-3.18

ROA (5Y Avg)-29.77%

Net Profit Margin (Annual)-412.95%

Month-to-Date Return-14.31%

Cash Flow / Share (TTM)$-2.01

EBITD / Share (Annual)$-3.45

Operating Margin (Annual)-449.94%

LT Debt / Equity (Annual)0.06x

P/CF (TTM)8.88x

ROI (5Y Avg)-57.52%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-3.35

P/TBV (Quarterly)1.65x

P/B Ratio (Annual)5.19x

Pretax Margin (TTM)-411.08%

Book Value / Share (Annual)$1.98

Price vs S&P 500 (13W)-5.55%

Beta0.41x

P/FCF (Annual)5.80x

Revenue / Share (TTM)$0.81

ROE (TTM)-141.95%

52-Week Low$5.45

vGradeC

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.83est. -0.65

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KURAKura Oncology, Inc.	C	B	C	$8.74
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Kura Oncology is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies. Its pipeline comprises small molecule drug candidates designed to target specific cancer signaling pathways.